TGF-β signaling identified as a new therapeutic target for osteoporosis treatment (IMAGE)

Editorial Office of West China School of Stomatology, Sichuan University

TGF-β signaling identified as a new therapeutic target for osteoporosis treatment

Caption

A recent study indicates that inhibiting TGF-β may enhance the efficacy of anti-sclerostin-based osteoporosis treatment by reactivating quiescent osteoblasts. In a bone-loss mouse model, combining TGF-β and sclerostin inhibition significantly increased bone mass compared to inhibiting sclerostin alone, suggesting an effective combination strategy.

Credit

German Tenorio from Openverse Image source link: https://openverse.org/image/7d2e339a-e418-43b0-a00f-0c3a43afab91?q=osteoblast&p=5

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.

License

CC BY-NC-ND

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.